Methylnaphthidate
Viewing r1 — May 12, 2026
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
HDMP-28 (methylnaphthidate) is a synthetic stimulant of the substituted phenidate class. It is a structural analog of methylphenidate, several times more potent at the DAT and with added SERT activity.[1] It blocks the recycling of dopamine, norepinephrine, and serotonin in the brain, amplifying all three signals simultaneously.[2]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
methylphenidate, ethylphenidate, isopropylphenidate +1 moremethylphenidate, ethylphenidate, isopropylphenidate, cocaine show less
Synthesized in 2001 by Deutsch et al. as a research tool for studying cocaine abuse treatment, methylnaphthidate was never developed for medical use.[3] It appeared on research chemical markets around 2014–2015, following earlier phenidate derivatives such as ethylphenidate.[1] It is now explicitly controlled in the United Kingdom, Canada, Germany, and Switzerland, while remaining unscheduled at the federal level in the United States.
Subjective effects include stimulation, wakefulness, appetite suppression, and mood elevation. The experience resembles Methylphenidate but may carry a warmer emotional tone — attributed to serotonin activity, though this has not been confirmed in controlled study.[4] Anxiety, restlessness, and low mood in the hours after use are characteristic unwanted effects.
Psychological dependence potential is high — animal studies show reinforcement equal to cocaine[5] — and the cardiovascular system bears the main acute toxicity burden. Serotonin activity adds interaction risks absent from Methylphenidate; combining with serotonin-raising drugs or MAOIs can trigger a life-threatening overheating and seizure response.[2] No human studies exist — all safety knowledge comes from animal data, transporter binding studies, and analogy to related phenidates.[6][7]
History[edit]
Discovery
Deutsch et al. first synthesized methylnaphthidate in 2001 as part of a series of methylphenidate analogs designed to study cocaine abuse treatment.[3] The naphthyl substitution proved several times more potent than the parent compound at the DAT. The compound was never pursued for therapeutic development — it existed purely as a pharmacological research tool.
Research chemical emergence
Despite appearing in the scientific literature since 2001, HDMP-28 did not surface on research chemical markets until approximately 2014–2015[1][4] — following earlier phenidate derivatives like ethylphenidate, which had appeared circa 2011–2013.
Regulatory and forensic attention
Several countries moved to control methylnaphthidate following its appearance on NPS markets — the United Kingdom scheduled it as Class B in 2017, and Germany listed it under its Novel Psychoactive Substances Act in 2016.[2]
The designation HDMP-28 comes from the compound's position in the Deutsch et al. synthesis series — the 28th in a line of high-dopamine-transporter-affinity methylphenidate analogs. The most consequential early behavioral study — Lile et al.'s 2003 rhesus monkey work — established that HDMP-28 was reinforced as readily as cocaine,[5] a finding that shaped its reputation as a compound warranting particular caution.
Chemistry[edit]
Structural class
Methylnaphthidate belongs to the substituted phenidate class — a family of piperidine-based compounds structurally derived from methylphenidate.[3] The key modification is replacement of a phenyl ring with a larger naphthyl (two-ring aromatic) group. This expands the aromatic surface, increases lipophilicity, and introduces SERT affinity absent in the parent compound.
Molecular identity
| Molecular formula | C₁₈H₂₁NO₂ |
| Molecular weight | 283.4 g/mol |
Methylnaphthidate is broken down primarily by ester hydrolysis — the same metabolic process that converts Methylphenidate to an inactive form.[1] The larger naphthyl ring is expected to slow this breakdown, giving methylnaphthidate a longer duration than the parent compound.[6]
Pharmacology[edit]
Mechanism of action
Methylnaphthidate blocks the recycling of dopamine, norepinephrine, and serotonin at their respective transporters — keeping all three neurotransmitters active in the synapse longer than they would otherwise be.[2][1]
The naphthyl ring changes the compound's transporter selectivity. Where methylphenidate acts mainly on dopamine and norepinephrine transporters, methylnaphthidate also binds the SERT at comparable strength — placing it pharmacologically closer to cocaine.[2][8] Norepinephrine transporter activity is inferred from class membership, not directly confirmed for this compound.safety citation needed
Pharmacokinetics
No pharmacokinetic studies have been conducted in humans. Community reports suggest oral onset within 1–10 minutes, with effects lasting 2–5 hours; insufflation produces faster onset and shorter duration.[4] The compound is longer-acting than Methylphenidate, attributed to slower ester hydrolysis driven by the naphthyl substitution.[6]
Neuroscience[edit]
Where it acts
As a potent DAT inhibitor, methylnaphthidate raises dopamine in the brain's reward circuit — the pathway running from the brainstem to the nucleus accumbens that drives motivation and reinforcement.[3] Animal studies show it maintained self-administration behavior as readily as cocaine, a direct measure of reinforcing potency.[5]
Why it matters
Dopamine drives compulsive wanting — the motivation to seek a substance — more than it drives pleasure. Methylnaphthidate's strong dopamine blockade amplifies this wanting, consistent with the compulsive redosing tendency reported for phenidate-class stimulants. Elevated serotonin may add a mood-modulating dimension, though whether this produces perceptible effects at typical doses remains untested.
Key unanswered questions include: how quickly methylnaphthidate occupies the dopamine transporter in the human brain — a kinetic property strongly predictive of abuse liability; whether SERT activity produces detectable subjective effects at typical doses; and whether repeated exposure causes lasting changes in dopamine receptor density, as occurs with other stimulants.
Subjective Effects[edit]
Methylnaphthidate brings sharp focus, elevated mood, and driven energy — the kind of stimulation that narrows attention to a task and makes fatigue disappear. There may be a quality of warmth absent from other phenidates, though whether that reflects genuine serotonin activity or observer variability isn't settled.[4]
It sits pharmacologically between methylphenidate and cocaine — more potent than the former, with a serotonin component that makes it unusual among phenidates. Reports describe the experience as qualitatively similar to methylphenidate, with possible differences in hedonic warmth.[4]
Effect Grid
Clear stimulant effects dominate — sustained focus enhancement, motivation enhancement, and thought acceleration are pronounced. Appetite suppression becomes significant. The SERT component may contribute mild mood elevation with possible entactogen-adjacent warmth not typical of purely catecholaminergic phenidates. Time alteration — typically perceived acceleration — may be noticed. Oral doses range 15–30 mg; insufflated 8–14 mg.
Cardiovascular effects become noticeable: elevated heart rate, mild abnormal heartbeat awareness, and vasoconstriction. Bruxism, dry mouth, and dehydration sensation emerge. Pupil dilation is likely. Excessive sweating may occur with physical activity.
Insomnia is expected if dosed within 6–8 hours of intended sleep. The offset phase brings cognitive fatigue, mild irritability, and reduced motivation as dopaminergic rebound begins.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Visual acuity enhancement · Auditory enhancement
Dry mouth · Insomnia · Muscle tension · Body high · Heart rate perception changes · Physical fatigue · Restlessness · Dehydration sensation · Excessive sweating · Nausea · Bruxism · Headache · Respiratory stimulation · Sexual arousal enhancement · Spontaneous body sensations · Tactile euphoria · Motor control enhancement · Dizziness · Tingling / electric sensations · Trembling · Vomiting
Heart rate perception changes · Physical fatigue · Restlessness · Dehydration sensation · Excessive sweating · Nausea · Bruxism · Headache · Respiratory stimulation · Sexual arousal enhancement · Spontaneous body sensations · Tactile euphoria · Motor control enhancement · Dizziness · Tingling / electric sensations · Trembling · Vomiting
Analysis enhancement · Information processing enhancement · Motivation enhancement · Cognitive fatigue · Immersion enhancement · Pattern recognition enhancement · Thought organization · Memory enhancement · Aesthetic enhancement · Cognitive dysphoria · Cognitive flexibility · Motivation suppression · Novelty enhancement · Creativity enhancement · Language enhancement · Cognitive impairment · Confusion · Thought connectivity · Thought disorganization · Thought loops
Immersion enhancement · Pattern recognition enhancement · Thought organization · Memory enhancement · Aesthetic enhancement · Cognitive dysphoria · Cognitive flexibility · Motivation suppression · Novelty enhancement · Creativity enhancement · Language enhancement · Cognitive impairment · Confusion · Thought connectivity · Thought disorganization · Thought loops
Irritability · Dysphoria · Emotional enhancement · Emotional lability · Emotional suppression · Mania
Emotional lability · Emotional suppression
Flow state · Sociability enhancement · Social connection · Self-control enhancement · Disinhibition · Emotional susceptibility
Disinhibition · Emotional susceptibility
Timeline
Initial awareness of mild alertness shift; subtle stimulation emerging below threshold of clear identification.
Building stimulation with focus sharpening and appetite suppression beginning. Cardiovascular activation becomes perceptible.
Full stimulant effects — sustained focus, motivation enhancement, wakefulness, and possible mood elevation from SERT activity. Cardiovascular effects at maximum.
Gradual diminution of stimulation. Residual wakefulness and appetite suppression persist. Cognitive fatigue begins emerging.
Residual fatigue, mild dysphoria, and appetite returning. Difficulty sleeping may persist for several hours.
⚠ Do not drive or operate machinery until fully rested — cognitive fatigue and residual stimulant effects may impair reaction time.
Safety[edit]
- Acute toxicity
- Moderate
- Chronic toxicity
- Moderate
- Withdrawal
- Mild
- Tolerance buildup
- moderate
- Tolerance reset
- 10 days
- Physical
- Negligible
- Psychological
- High
- Compulsive redosing
- High
- Dose escalation
- Moderate
- Cross-tol.
- methylphenidate · ethylphenidate · isopropylphenidate
Toxicity
Acute toxicity
No human fatalities or lethal dose data exist for methylnaphthidate.[7] By pharmacological class, high doses carry risk of dangerous blood pressure elevation, rapid heart rate, irregular heart rhythm, and overheating — particularly with physical exertion or in combination with serotonergic drugs.[9][10]
Chronic toxicity
No chronic toxicity data exist for methylnaphthidate. For the phenidate class broadly, chronic harms include cardiovascular strain, psychological dependence, and cognitive disruption.[11] All assessments for this compound specifically are inferred from class analogy.safety citation needed
Psychological risks
Compulsive redosing is the primary behavioral risk — animal models place reinforcing efficacy equal to cocaine.[5] At high doses, anxiety, paranoia, and restlessness are expected; prolonged heavy use can produce hallucinations and disordered thinking, though no such cases have been reported for this compound.
A low-mood rebound effect typically follows use — fatigue, depression, irritability, and cognitive fatigue as dopamine levels recover over hours.
Tolerance and dependence
Tolerance develops through dopamine receptor adaptation and is expected to follow a moderate time course, consistent with the phenidate class.inferred Physical dependence is low — no phenidate derivative has produced a withdrawal requiring medical management.inferred
Psychological dependence potential is moderate to high, based on animal reinforcement data showing efficacy equivalent to cocaine.[5] Withdrawal may bring low mood, excess sleep, appetite enhancement, and thought deceleration.
Drug interactions
The triple monoamine reuptake inhibitor profile creates interaction risks across three neurotransmitter systems. Serotonin transporter activity adds dangers not present with methylphenidate.
Serotonergic interactions
MAOIs block serotonin breakdown entirely; adding methylnaphthidate's serotonin reuptake blockade on top can cause a life-threatening overheating and seizure response.safety citation needed MDMA and tramadol are similarly hazardous — both raise serotonin through separate mechanisms, and the combined burden risks extreme serotonergic overload, dangerous overheating, and cardiovascular crisis.[9][10]
Dopaminergic and sympathomimetic interactions
Cocaine combined with methylnaphthidate produces additive monoamine elevation and extreme cardiovascular strain — dangerous blood pressure elevation, vessel constriction, and irregular heart rhythm.safety citation needed
Alcohol
Co-administration with alcohol may convert the methyl ester to an ethyl ester through an enzymatic interaction, by analogy with the well-characterized methylphenidate-ethanol reaction.[12][13][14] This conversion has not been confirmed for methylnaphthidate.inferred
All interaction severity ratings for methylnaphthidate are inferred from pharmacological mechanism and class-level evidence. No substance-specific adverse event case reports confirm any interaction. The tramadol, MDMA, and cocaine interactions are classified as potentially lethal based on mechanistic analysis, not clinical observation.
Contraindications
All contraindications are inferred from pharmacological class. No methylnaphthidate-specific data exist.
- MAOI use: Absolute contraindication. Risk of dangerous blood pressure crisis and serotonin syndrome.safety citation needed
- Pre-existing heart conditions: Absolute contraindication. Blood pressure elevation, rapid heart rate, and vessel constriction pose acute risk of cardiac events and stroke.safety citation needed
- History of psychosis or bipolar disorder: Relative contraindication. Potent dopaminergic stimulation can trigger or worsen psychotic and manic episodes.inferred
- Concurrent serotonergic medication: Relative contraindication. SSRIs, SNRIs, triptans, and similar drugs combined with serotonin reuptake blockade increase serotonin toxicity risk.safety citation needed
- Seizure disorders: Relative contraindication. Stimulant-class seizure threshold lowering is expected.inferred
Harm Reduction[edit]
Forms & Identification
Methylnaphthidate circulates exclusively through research chemical vendors as a powder or crystalline solid. No pharmaceutical formulations exist. Batch purity and identity cannot be assumed — test every acquisition with appropriate reagent kits, and note that a positive result confirms only the compound class, not purity or dose accuracy.
Volumetric dosing — dissolving a weighed quantity in a measured volume of liquid and dosing by volume — is strongly preferred over weighing individual powder doses. The active dose range is narrow enough that milligram-scale imprecision meaningfully affects both the experience and the risk.
Set & Setting
With reinforcing efficacy comparable to cocaine in animal models, methylnaphthidate warrants careful attention to the psychological context of use. A clear intention and a predetermined endpoint reduce the risk of compulsive redosing — the primary behavioral hazard of potent dopamine reuptake inhibitors.
Avoid hot environments, sustained physical exertion, and dehydration. All amplify cardiovascular strain from catecholaminergic stimulation.
Guidelines
- Test every batch with appropriate reagent kits before use
- Use volumetric dosing rather than weighing individual doses of powder
- Start with a low dose and wait for full onset before considering redosing — oral onset may take up to 10 minutes
- Set a firm limit on total dose and number of redoses before the session begins
- Keep the compound out of arm's reach during the session to reduce impulsive redosing
- Avoid insufflation if possible — the compressed, intensified onset increases reinforcing potential and cardiovascular strain
- Ensure access to water and a cool environment
- Do not use on consecutive days; allow at least 48 hours between sessions
- Do not combine with other stimulants, serotonergic substances, or alcohol
Aftercare & Integration
The post-stimulation period typically brings low mood, fatigue, irritability, and difficulty concentrating — a predictable dopamine rebound effect, not a sign of lasting damage.
Prioritize sleep, hydration, and regular meals in the 24–48 hours following use. Avoid caffeine and other stimulants during the comedown. If low mood persists beyond 72 hours, or cravings feel difficult to manage, speak with a healthcare provider or counselor.
Recovery & Support
The reinforcing efficacy data suggest regular use carries meaningful risk of developing a compulsive pattern. If use has escalated in frequency or dose, or attempts to stop have been unsuccessful, structured support is appropriate.
Resources include SAMHSA's National Helpline (1-800-662-4357, US), SMART Recovery, and local addiction services. Stimulant use disorders respond to cognitive-behavioral therapy and contingency management; no pharmacological treatment is established, making behavioral approaches the primary recovery pathway.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: chest pain, severe headache, seizure, loss of consciousness, extreme agitation with confusion, or body temperature hot to the touch through clothing all indicate a medical emergency rather than ordinary discomfort.
- 1. Call emergency services immediately if any of the above signs are present
- 2. Place the person in a cool, quiet environment while waiting for help
- 3. If unconscious but breathing, place in the recovery position (on their side, airway clear)
- 4. Do not restrain an agitated person unless they are at immediate risk of self-harm
- 5. Do not induce vomiting
- 6. Monitor breathing continuously until help arrives
Tell the dispatcher: the substance name (methylnaphthidate or HDMP-28), the approximate amount taken, the time of last dose, the route of administration, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency.
No reversal agent exists for stimulant overdose.
Legal Status[edit]
As of May 2026, methylnaphthidate is not uniformly scheduled internationally — its legal status varies significantly by jurisdiction.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Not federally scheduled | Not listed under DEA Schedule II (which covers methylphenidate). Federal Analogue Act (21 U.S.C. § 813) may apply when intended for human consumption. New Mexico schedules it at state level[2] |
| United Kingdom | Class B (Misuse of Drugs Act 1971) | Scheduled 31 May 2017 under broad phenidate NPS scheduling[2] |
| Canada | Schedule III (Controlled Drugs and Substances Act) | Controlled substance[2] |
| Germany | Controlled (NpSG) | Listed under Neue-psychoaktive-Stoffe-Gesetz since 26 November 2016[2] |
| Switzerland | Illegal (Verzeichnis E) | Listed since December 2015[2] |
| Turkey | Illegal | Controlled since February 2016[2] |
| Australia | Unconfirmed | Requires verification against TGA ARTG databasecitation needed |
| New Zealand | Unconfirmed | Requires verification against Misuse of Drugs Actcitation needed |
Analog act considerations
In the United States, methylnaphthidate's structural similarity to the Schedule II substance methylphenidate may bring it under the Federal Analogue Act (21 U.S.C. § 813) when intended for human consumption. No such prosecution has been publicly reported.
Legal status changes frequently and varies significantly by jurisdiction. This information reflects known status as of May 2026 and is not legal advice.
references
- [1]
- [2]
- [3] ^abcdDeutsch HM, Ye X, Shi Q, Liu Z, Schweri MM (2001) Synthesis and pharmacology of site specific cocaine abuse treatment agents: a new synthetic methodology for methylphenidate analogs based on the Blaise reaction — European Journal of Medicinal Chemistry PMID:11461755
- [4]
- [5]
- [6] ^abcMuhammed Ajeebsanu M, Subhahar MB, Karakka Kal AK, Philip M, Perwad Z, Karatt TK, Graiban FM, Joseph M, Jose SV (2024) Comprehensive metabolic investigation of dopamine reuptake inhibitor HDMP-28 in equine liver microsomes and Cunninghamella elegans for doping control — Drug Testing and Analysis doi:10.1002/dta.3642